Aeterna
Zentaris Inc. introduced that statistics from two Phase 2 trials in renal cell
carcinoma (RCC) regarding the Company's oral anticancer medication, perifosine,
happen to published within the June 2012 issue of Cancer, a journal of the
American Cancer Society.
The
article is referred to as, "Two Phase 2 Trials of the Novel Akt Inhibitor
Perifosine in Affected individuals along with Advanced Renal Cell Carcinoma after
Development on Vascular Endothelial Growth Factor-Targeted Therapy.”
It
outlines perifosine's exercise as monotherapy in affected individuals along
with advanced RCC that was comparable to current second-line representatives.
Both objective tumor solutions and prolonged disorder equilibrium were really
seen, and perifosine was clearly tolerated with the 100mg daily dose utilized
in this trial. Ultimately, the authors conclude the fact that compound can deserve
further investigation within this indication in conjunction with available
therapies.
No comments:
Post a Comment